The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.

BACKGROUND AND OBJECTIVES In this study the impact of gender, age, type of M-component and concentration of immunoglobulins on the risk of malignant transformation in monoclonal gammopathy of undetermined significance (MGUS) was assessed. DESIGN AND METHODS We identified 1,247 cases of MGUS in the period 1978 to 1993 in North Jutland County, Denmark. Data on cancer occurrence in the MGUS cohort were obtained from the Danish Cancer Registry. The expected numbers of incident cancer cases were calculated from age-, sex-, county-, and period-specific cancer incidence rates. The impact of the variables mentioned above on the risk of malignant transformation was analyzed in Poisson regression models. RESULTS The relative risk of IgA compared to IgG was 1.8 (95% confidence interval, 1.1-3.0), while the relative risk of IgM compared to IgG was 1.1 (0.7-1.9). For all three types of MGUS, the risk of malignant transformation was higher among females than among males, and the risk increased with increasing concentration of immunoglobulin with very high risks for the patients with the highest levels of immunoglobulin. Hypogammaglobulinemia was associated with malignant transformation in patients with IgG type MGUS. For IgG and IgM MGUS, the risk decreased with increasing age and with follow-up beyond one year. INTERPRETATION AND CONCLUSIONS Female sex, IgA M-component type and high concentration of the immunoglobulin comprising the M-component were associated with a high risk of malignant transformation. Hypogammaglobulinemia, young age at diagnosis and short follow-up were risk factors in particular for those with IgG MGUS.

[1]  敦 戸川,et al.  Monoclonal gammopathy of undetermined significance (MGUS) , 2002 .

[2]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[3]  R. Kyle,et al.  Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.

[4]  H. Storm,et al.  The Danish Cancer Registry--history, content, quality and use. , 1997, Danish medical bulletin.

[5]  M. Dimopoulos,et al.  Prognostic features of asymptomatic multiple myeloma , 1997, British journal of haematology.

[6]  T. Zemunik,et al.  Prognosis in monoclonal gammopathy of undetermined significance , 1997, British journal of haematology.

[7]  R. Casale,et al.  Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  R. Casale,et al.  The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. , 1997, Acta haematologica.

[9]  L. Baldini,et al.  Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. , 1996, Blood.

[10]  J. Coebergh,et al.  Malignant transformation of monoclonal gammopathy of undetermined significance among out‐patients of a community hospital in Southeastern Netherlands , 1995, British journal of haematology.

[11]  M. Raymond,et al.  Monitoring of monoclonal gammopathies: rational use of densitometry and rate nephelometry. , 1994, Clinical biochemistry.

[12]  R A Kyle,et al.  "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.

[13]  A. López-Guillermo,et al.  Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance , 1992, British journal of haematology.

[14]  J. Bergua,et al.  [Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases]. , 1991, Sangre.

[15]  R. Casale,et al.  Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications. , 1991, Panminerva medica.

[16]  R. Kyle,et al.  The spectrum of IgM monoclonal gammopathy in 430 cases. , 1987, Mayo Clinic proceedings.

[17]  Norman E. Breslow,et al.  The design and analysis of cohort studies , 1987 .

[18]  E. Schmidt,et al.  Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy. , 2009, Scandinavian journal of haematology.

[19]  S. Clejan,et al.  Long-term study of gammopathies. Clinically benign cases showing transition to malignant plasmacytomas after long periods of observation. , 1986, Clinical biochemistry.

[20]  M. Vicariot,et al.  Monoclonal gammopathies in the adult population of Finistère, France. , 1982, Journal of clinical pathology.

[21]  A. Carter,et al.  The Physiopathological Significance of Benign Monoclonal Gammopathy: a Study of 64 Cases , 1980, British journal of haematology.

[22]  B G Johansson,et al.  Agarose gel electrophoresis. , 1972, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[23]  U. Axelsson,et al.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .